ebola
viru
caus
one
danger
diseas
affect
human
primat
ebola
viru
diseas
evd
character
sever
cours
gener
intox
high
mortal
rate
reach
genu
ebola
viru
ebolaviru
member
filovirida
famili
viral
particl
virus
filovirida
famili
order
mononegaviral
characterist
filamentlik
shape
genom
repres
singlestrand
rna
neg
polar
three
filoviru
genera
ebolaviru
marburgviru
cuevaviru
ebolavirus
marburgvirus
mark
pathogen
human
ebola
viru
ebov
danger
pathogen
date
five
ebola
viru
speci
identifi
bundibugyo
ebolaviru
bdbv
zair
ebolaviru
zebov
reston
ebolaviru
restv
sudan
ebolaviru
sudv
tai
forest
ebolaviru
tafv
zebov
sudv
bdbv
danger
human
evd
first
detect
yambuku
democrat
republ
congo
northern
part
zair
nzara
sudan
year
evd
agent
ebola
viru
ebolaviru
first
isol
patient
live
near
ebola
river
sinc
time
pathogen
isol
day
evd
outbreak
occur
largest
turn
epidem
case
claim
live
peopl
time
epidem
neither
prevent
therapeut
agent
evd
licens
world
time
specif
heterolog
hors
immunoglobulin
ebola
fever
develop
virolog
center
research
institut
russian
defens
ministri
urgent
prophylaxi
treatment
highrisk
group
immunoglobulin
protect
activ
experi
monkey
due
high
mortal
rate
last
evd
epidem
spread
viru
outsid
africa
committe
conven
earli
august
committe
conclud
evd
outbreak
extraordinari
event
intern
import
significantli
acceler
develop
prevent
therapeut
agent
evd
year
sever
vaccin
develop
current
differ
phase
clinic
trial
two
vaccin
develop
russia
regist
medic
use
effect
econom
way
protect
infecti
diseas
vaccin
prevent
howev
vaccin
approv
use
begin
last
ebola
outbreak
develop
first
vaccin
ebola
fever
began
identif
viru
mainli
focus
attempt
creat
effect
vaccin
base
inactiv
ebola
viru
fig
first
candid
vaccin
basi
heat
formalininactiv
ebola
viru
test
guinea
pig
exhibit
protect
despit
high
efficaci
guinea
pig
vaccin
provid
proper
level
protect
primat
lethal
infect
anoth
disadvantag
vaccin
extrem
danger
product
condit
fact
prevent
introduct
vaccin
clinic
practic
fig
took
year
develop
effect
safe
vaccin
associ
fact
express
featur
main
protect
antigen
ebola
viru
gp
remain
unclear
long
time
breakthrough
came
articl
volchkov
et
al
publish
shown
rna
edit
viral
polymeras
result
sever
gp
form
fulllength
envelop
antigen
gp
fig
studi
found
gp
express
eukaryot
cell
undergo
extens
glycosyl
subsequ
happen
critic
preserv
immunogen
antigen
protect
understand
biosynthesi
peculiar
variou
gp
form
led
first
gener
candid
dna
vaccin
plasmid
vector
use
construct
vaccin
contain
fulllength
glycoprotein
gp
gene
nucleoprotein
gene
ebola
viru
vaccin
show
suffici
high
protect
level
anim
studi
efficaci
dna
vaccin
carri
ebola
viru
glycoprotein
gp
gene
higher
vaccin
carri
ebola
viru
nucleoprotein
np
gene
howev
use
vaccin
requir
multipl
time
administr
drug
achiev
high
level
protect
critic
limit
factor
effect
use
epidem
develop
problem
multipl
vaccin
resolv
recombin
viral
vector
technolog
develop
figur
contrast
dna
vaccin
vector
provid
high
longlast
level
target
transgen
express
enabl
induct
protect
immun
one
two
immun
experi
direct
comparison
demonstr
much
faster
format
immun
respons
recombin
viral
vector
base
candid
vaccin
compar
plasmid
dnabas
vaccin
note
immun
associ
humor
immun
respons
also
pronounc
cellular
immun
respons
later
occur
key
aspect
protect
ebola
fever
variou
studi
demonstr
cellular
immun
play
key
role
format
protect
immun
ebola
viru
direct
deplet
cell
monkey
immun
evd
caus
decreas
vaccin
protect
immun
result
death
anim
ebola
viru
infect
cell
deplet
protect
respons
also
decreas
immun
monkey
anim
die
time
passiv
transfer
hightit
polyclon
antibodi
ebola
viru
vaccin
monkey
naiv
one
provid
incomplet
protect
lethal
infect
anim
die
despit
high
titer
common
igg
ntab
peripher
blood
serum
import
cellular
immun
indirectli
confirm
fact
peripher
blood
peopl
surviv
evd
contain
increas
number
specif
cell
compar
blood
healthi
peopl
time
number
specif
cell
actual
increas
summar
thirtyyear
histori
studi
aim
develop
effect
evd
vaccin
may
conclud
ideal
vaccin
ebola
fever
induc
cellular
humor
immun
respons
administ
minimum
number
time
induc
prolong
protect
immun
use
recombin
viral
vector
provid
indic
condit
regard
vaccin
develop
basi
condit
support
promis
direct
develop
ebola
vaccin
last
evd
epidem
bulk
develop
vaccin
ebola
fever
base
use
recombin
viral
vector
express
protect
antigen
gp
fulllength
ebola
viru
surfac
glycoprotein
phase
clinic
trial
recombin
vesicular
stomat
viru
vsv
base
vaccin
complet
vsvbase
vaccin
encod
gp
zair
kikwit
sudan
ebola
viru
demonstr
efficaci
seri
preclin
trial
primat
high
immunogen
vsvbase
vaccin
demonstr
seri
clinic
trial
vaccin
induc
high
level
gpspecif
antibodi
tabl
associ
protect
primat
studi
clinic
trial
conduct
europ
africa
demonstr
use
vsvbase
vaccin
variou
dose
lead
induct
humor
immun
respons
level
gpspecif
antibodi
similar
phase
clinic
trial
guinea
use
ring
vaccin
demonstr
efficaci
vaccin
recombin
human
adenoviru
serotyp
base
vaccin
encod
fulllength
zebov
gp
pass
phase
clinic
trial
china
administr
high
vaccin
dose
vp
induc
high
level
gpspecif
antibodi
titer
volunt
month
vaccin
tcell
respons
maximum
day
decreas
day
studi
six
month
vaccin
gp
antibodi
titer
significantli
decreas
amount
tabl
volunt
revaccin
month
primari
vaccin
four
week
revaccin
vaccin
induc
high
level
gpspecif
antibodi
titer
blood
serum
volunt
one
year
revaccin
titer
gpspecif
antibodi
blood
serum
volunt
one
main
problem
limit
use
vector
wide
preval
preexist
immun
presenc
neutral
antibodi
popul
presenc
antibodi
vaccin
shown
lead
induct
lower
gpspecif
humor
tcell
respons
vaccin
howev
clinic
trial
china
demonstr
use
high
dose
base
vaccin
may
reduc
neg
effect
preexist
immun
format
gpspecif
immun
respons
anoth
way
solv
problem
preexist
immun
vaccin
vector
use
recombin
vector
serotyp
rare
preexist
immun
human
popul
eg
human
adenoviru
serotyp
adenoviru
chimpanze
serotyp
vaccin
pass
phase
clinic
trial
progress
phase
vaccin
vector
carri
gp
gene
mayingazair
ebola
viru
gp
gene
gulusudan
ebola
viru
result
phase
clinic
trial
conduct
unit
state
demonstr
vaccin
induc
high
level
gpspecif
antibodi
titer
tcell
respons
associ
protect
nhp
model
howev
clinic
trial
england
report
low
titer
gpspecif
antibodi
mean
valu
reach
level
protect
primat
tcell
respons
maximum
day
studi
decreas
day
one
problem
develop
vaccin
evd
reduct
protect
immun
respons
month
immun
problem
solv
use
heterolog
primeboost
vaccin
figur
vaccin
strategi
ebola
recommend
promis
one
also
note
recombin
viral
vector
certain
disadvantag
preexist
immun
vaccin
vector
incorrect
process
target
antigen
use
mvabas
vaccin
vector
lack
data
durat
protect
immun
respons
vsvbase
vaccin
vector
elimin
use
heterolog
vaccin
figur
seri
preclin
trial
primat
demonstr
homolog
vaccin
base
vector
result
shortterm
protect
week
vaccin
regimen
protect
decreas
month
heterolog
mva
vaccin
protect
month
boost
heterolog
vaccin
base
recombin
modifi
vaccinia
ankara
mva
viru
pass
phase
clinic
trial
vaccin
vector
carri
gp
gene
mayingazair
ebola
viru
gulusudan
ebola
viru
mva
vector
multival
mvabnfilo
carri
gp
gene
ebov
sudv
marv
np
gene
tafv
use
heterolog
vaccin
enabl
manyfold
amplif
humor
cellular
immun
respons
furthermor
use
vaccin
base
mva
combin
preserv
high
titer
gpspecif
antibodi
month
boost
russia
heterolog
combin
vector
evd
vaccin
primeboost
vaccin
develop
accord
recommend
base
two
recombin
viral
vector
express
ebola
viru
glycoprotein
recombin
vesicular
stomat
viru
vsvgp
recombin
human
adenoviru
serotyp
adgp
seri
preclin
trial
primat
demonstr
immun
vaccin
provid
protect
infect
anim
week
immun
month
immun
clinic
trial
safeti
immunogen
demonstr
vaccin
provid
high
safeti
immunogen
level
healthi
volunt
seriou
advers
event
ae
occur
vaccin
safeti
studi
ae
mild
moder
develop
within
first
day
vaccin
resolv
within
next
day
common
ae
pain
inject
site
headach
weaknessfatigu
ae
typic
recombin
viral
vector
vaccin
vaccin
efficaci
assess
use
variou
paramet
humor
cellular
immun
respons
seroconvers
level
mean
titer
zebovgpspecif
igg
day
studi
group
receiv
full
dose
vaccin
importantli
immun
vsvgp
alon
dose
induc
antibodi
titer
day
significantli
lower
titer
obtain
heterolog
vaccin
day
viru
neutral
assay
detect
viru
neutral
antibodi
mean
titer
volunt
receiv
full
dose
vaccin
cellular
immun
respons
assess
ifngamma
product
peripher
blood
mononuclear
cell
antigen
challeng
respons
detect
volunt
day
studi
despit
publish
data
neg
effect
preexist
immun
adenovirus
signific
correl
level
neutral
antibodi
level
gpspecif
humor
cellular
respons
case
immun
healthi
volunt
vsv
adbas
vaccin
indic
use
heterolog
vaccin
neutral
neg
effect
preexist
immun
human
adenoviru
serotyp
vaccin
vector
base
find
preclin
clinic
trial
demonstr
high
vaccin
efficaci
safeti
evd
vaccin
develop
produc
gamaleya
research
center
epidemiolog
microbiolog
licens
russian
feder
evd
pose
seriou
threat
global
secur
sinc
ebola
viru
first
detect
outbreak
record
mainli
occur
rural
area
east
central
africa
outbreak
began
three
countri
west
africa
chang
situat
first
case
viru
detect
urban
center
viru
could
spread
outsid
africa
europ
north
america
spread
ebola
viru
outsid
africa
evd
epidem
high
mortal
rate
solid
reason
activ
develop
effect
prevent
therapeut
remedi
date
variou
clinic
trial
africa
europ
us
russia
shown
good
safeti
immunogen
profil
sever
evd
vaccin
eight
vaccin
differ
phase
clinic
trial
two
vaccin
gamevac
gamevaccombi
develop
produc
gamaleya
research
center
epidemiolog
microbiolog
current
licens
vaccin
ebola
fever
gamevaccombi
vaccin
heterolog
vsv
vaccin
gamevac
vaccin
homolog
vaccin
conclus
note
despit
high
price
alreadi
paid
mankind
learn
import
lesson
becom
obviou
time
drive
global
threat
public
health
possibl
effort
polit
leader
expert
key
pharmaceut
player
consolid
combin
work
expert
differ
field
enabl
fast
introduct
novel
advanc
vaccin
practic
medicin
obvious
gain
experi
use
futur
time
develop
vaccin
danger
viral
infect
prevent
measur
absent
moment
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
caus
coronaviru
zika
viru
diseas
etc
